drugset

drugset / Trial / NCT00699790

Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

NCT00699790 ↗

Phase 2 Completed 58 enrolled Bristol-Myers Squibb

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether a CCR2 antagonist (BMS-741672) improves glucose homeostasis in drug-naive type 2 diabetic patients

Timeline

Start: 2009-02
Primary completion: 2009-12
Completion: 2009-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-741672	Small molecule	50 mg	Oral

Indications